Editorial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 14, 2025; 31(2): 99443
Published online Jan 14, 2025. doi: 10.3748/wjg.v31.i2.99443
Current status of drug therapy for chronic hepatitis B
Chuang Jiang, Zhi-Hong Zhang, Jia-Xin Li
Chuang Jiang, Zhi-Hong Zhang, Jia-Xin Li, Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Jia-Xin Li, Department of General Surgery, Dafang County People's Hospital, Bijie 551600, Guizhou Province, China
Author contributions: Jiang C, Zhang ZH and Li JX contributed to this paper; Jiang C designed the overall concept and outline of the manuscript; Zhang ZH and Li JX contributed to the discussion and design of the manuscript; Jiang C and Li JX contributed to the writing, and editing the manuscript, and review of literature.
Supported by the Project of Guizhou Provincial Department of Science and Technology, No. Qiankehechengguo-LC[2024]109.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jia-Xin Li, MD, Assistant Professor, Chief Doctor, Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. lijiaxin@scu.edu.cn
Received: July 22, 2024
Revised: November 4, 2024
Accepted: November 25, 2024
Published online: January 14, 2025
Processing time: 148 Days and 14.8 Hours
Core Tip

Core Tip: Chronic hepatitis B poses a serious threat to human health, and drug treatment is the most important method. The purpose of treatment is to sustainably inhibit virus replication and even achieve clinical cure, prevent or slow down disease progression, and reduce the incidence of cirrhosis and hepatocellular carcinoma. The widely used drugs at present are interferon and nucleoside/nucleotide analogue. On the premise of ensuring the efficacy, increasing drug safety and reducing side effects is an important research direction of anti-hepatitis B virus treatment.